Market-Moving News for September 4th

Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo

Immuron Limited ((ASX: IMC, NASDAQ:IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports.A copy of the publication can

Shares of software companies are trading lower amid a rotation out of technology and AI-related stocks. Rising inflation concerns and elevated oil prices are fueling expectations for further Fed tightening, while elevated borrowing costs could weigh on demand, valuations and debt metrics.

C3.ai vs. UiPath: Which AI-Driven Tech Stock Is a Better Buy in 2026?

The article compares C3.ai and UiPath as investments in the agentic AI automation space. UiPath is recommended as the better buy due to its profitability, positive free cash flow, and consistent growth trajectory. C3.ai, while showing recent improvements like positive free cash flow and 73% quarter-over-quarter booking growth, remains unprofitable with substantial net losses and is still in early restructuring stages under CEO Thomas Siebel.

UiPath Announces Expanded Snowflake Partnership With Two-Way Data Integration, Listing On Snowflake Marketplace

UiPath Expands Partnership With BDO To Build Agentic AI Solutions

UiPath and BDO USA will jointly develop AI agents targeting risk management, controls transformation, enterprise compliance and other Office of the CFO activities.

Shares of space-related companies are trading lower, possibly as Rocket Lab extended losses, falling over 8% after an analyst cut its price target following a delay to its Neutron rocket’s first launch, weighing on peers.